Наша группа организует более 3000 глобальных конференций Ежегодные мероприятия в США, Европе и США. Азия при поддержке еще 1000 научных обществ и публикует более 700 Открытого доступа Журналы, в которых представлены более 50 000 выдающихся деятелей, авторитетных учёных, входящих в редколлегии.
Журналы открытого доступа набирают больше читателей и цитируемости
700 журналов и 15 000 000 читателей Каждый журнал получает более 25 000 читателей
Moges Woldemeskel
Renal Cell Carcinoma (RCC) is the most common primary renal neoplasm in humans and domestic animals such as dogs, cats and horses. Various subtypes are recognized in both humans and animals. Advances in biomedical sciences have developed hitherto unprecedented extraordinary cancer therapeutic options varying from sophisticated surgery to immunotherapy and gene therapy. Treatment regimens employed, response to treatments and prognosis vary based on the subtypes of RCC, degree of malignancy, metastasis and stage of the neoplasm. Surgery is the main treatment for most RCCs. Drug resistance has long been a challenge in cancer treatment. New insights in cancer treatment such as molecular targeted therapy including nano-medicine against chemo-resistance are among the contemporary developments targeting cancers. This mini review highlights on the occurrence and significance of RCC in humans and animals, briefly summarizes the various subtypes reported and the treatment regimens executed.